Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cyto-Facto

Request full access

GMP-compliant manufacturing services for gene and cell therapies

Kobe, JapanFounded 2022Biotech & Life Sciences

About Cyto-Facto

Cyto-Facto Inc., founded in October 2022 by Shin Kawamata, is a contract development and manufacturing organization (CDMO) specializing in gene and cell therapy products. The company spun out of the Foundation for Biomedical Research and Innovation at Kobe (FBRI) in April 2023, taking over the operations of the Cell Therapy Development Center (RDC). The RDC was notably the first site in Asia to commercially produce the CAR-T cell therapy product, Kymriah, for Novartis.

The company provides a range of services including GMP-compliant manufacturing, quality control testing, process development, and consulting for cell and gene preparations. It serves biotechnology and pharmaceutical companies by manufacturing investigational products for clinical trials and commercial-scale products. Cyto-Facto handles therapies using products like CAR-T cells and mesenchymal stem cells (MSC). Its business model is based on offering contract manufacturing (CMO) and contract development and manufacturing (CDMO) services.

A key product developed by the company is CytoFactory 4.0™, a cloud-based, GxP-compliant manufacturing management system designed to digitize and optimize the entire cell manufacturing process. This platform handles everything from raw material intake and inventory control to cell processing, quality testing, and shipment, aiming to reduce costs and improve efficiency. By making manufacturing records fully digital, it also supports regulatory compliance and process improvement.

The founder and CEO, Shin Kawamata, MD, PhD, has an extensive background in pathology, hematology, and stem cell biology, with experience at Novartis Research Institute and Stanford University. He served as the director of the RDC at FBRI before establishing Cyto-Facto. The company has secured Series A and B funding from investors including MPower Partners, D3, Asahi Kasei, Mitsubishi Corporation, and Kobe University Capital.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
82.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jun 2025 $9.2M $37M MPower Partners · Sumitomo · FUJIFILM ↗
SERIES A✓Equity / VC Apr 2024 $9.2M $37M SMBC Venture Capital · MPower Partners · Mitsubishi · Kobe University Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Cyto-Facto website traffic

Latest recorded traffic for Cyto-Facto is 1.4K monthly website visits, down 70.2% over the last three months. Cyto-Facto's team grew 50% over the past year.

Latest monthly visits1.4K 3-month web change-70.2% 1-year team growth+50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cyto-Facto in the Kobe ecosystem

Live from Dealroom

The Cyto-Facto office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • D3
  • Japan Finance
  • Kobe Shinkin Bank

Series A7 investors entered at this stage

  • MPower Partners
  • SMBC Venture Capital
  • Mitsubishi
  • Kobe University Capital
  • Mizuho Capital
  • Sumitomo
  • FUJIFILM

Other known investors1 additional known investor

  • Asahi Kasei Ventures
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇯🇵 Japan100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cyto-Facto on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cyto-Facto’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.